Clinical trial NCT03615053: Personalized Medicine for Canadians With Hemophilia
Official title: Personalized Medicine for Canadians With Hemophilia: a Pragmatic Evaluation of the Web-Accessible Population Pharmacokinetics Service- Hemophilia (WAPPS-Hemo) Tailored Dosing.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Hemophilia A
Hemophilia B
Keywords: pharmacokinetics
popPK
PK
Hemophilia
Lead sponsor: McMaster University
Sponsor class: OTHER
First posted: 2018-08-03
Enrollment: 600
Sex: ALL
Minimum age (years): 6
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: The PMCH study is a Canadian multicentre, open-label, historically-controlled clinical trial to evaluate the effects of implementing WAPPS-Hemo PopPK-based tailoring of hemophilia prophylaxis regimens using the tailoring dosing function of the WAPPS-Hemo system (WAPPS-Hemo clinical calculator). The study has a non-inferiority design for the primary efficacy and safety outcomes.
Primary purpose: OTHER

Brief summary: Performing an individual pharmacokinetic (PK) estimate is only the first step in implementing tailored prophylaxis, which requires using the PK profile information to design a personalized treatment regimen matching the treatment needs of individual patients. The overarching goal of WAPPS-Hemo is to provide an easy-to-use web application supporting all the steps needed to accomplish tailoring care of individual patients by matching their unique characteristics to the most appropriate treatment regimen, realizing the promise of personalized medicine.

This study will assess the impact of adopting population PK (popPK) based tailored prophylaxis in clinical practice, including proportion of patients eligible for tailoring, and encountered barriers. The impact on patient important outcomes and on societal outcomes, particularly financial impact, vs. current standardized regimens will be measured. It is hypothesized that WAPPS-Hemo, via estimation of precise individual PK profiles and by supporting the simulation of treatment regimens will:

1. improve or maintain patient important outcomes, while reducing wastage of factor concentrates; and
2. establish best practices and effective knowledge translation strategies for the implementation of personalized medicine.

Additionally, a solid base of data will be generated to model the bleeding risk of severe hemophilia A/B patients undergoing tailored prophylaxis which will enable evaluation of a combination of patient and treatment characteristics predictive of individual bleeding risk.

Detailed description: The PMCH study is a Canadian multicentre, open-label, historically-controlled clinical trial to evaluate the effects of implementing WAPPS-Hemo PopPK-based tailoring of hemophilia prophylaxis regimens using the tailoring dosing function of the WAPPS-Hemo system (WAPPS-Hemo clinical calculator).

The study start date at each centre are staggered by 1-3 months in a modified wedge-shaped design, to allow better differentiation of the effect of the intervention from unrelated but concomitant changes in other aspects of care in the Canadian landscape. Outcomes of interest will be measured for one year prior and for one year after the implementation of the WAPPS-Hemo regimen tailoring procedure.

The two main objectives of this study are:

1. Evaluate the applicability and effectiveness of WAPPS-Hemo PopPK-based tailoring of factor concentrate regimens.
2. Generate a solid base of data to model the bleeding risk of severe hemophilia A/B patients on prophylaxis, evaluating the contribution of patient and treatment characteristics to individual bleeding risk to be reduced by the tailored prophylaxis approach.

PMCH will objectively measure the impact of adopting a PopPK based tailoring of hemophilia treatment. The first goal will be minimizing the occurrence of bleeding events in the hemophilia population. The bleeding rate of Canadian hemophilia patients is still measurable at 2-4 spontaneous joint bleeds per year, which in turn reduce quality of life and consume health resources. It is expected that optimizing treatment goal and modalities will reduce this burden, or at least will not increase it, allowing the pursuit the second goal: minimize the use of resources and prompt a more equitable distribution of factor concentrates. For some patients, standard prophylaxis dosing leads to excessive use of concentrates. It is expected that a small but sizeable proportion of the patient population will be able to successfully reduce their factor concentrate consumption. The third goal will be to generate an evidence-based approach to identify the appropriate target goal(s) for individual patients by modelling the components of their risk of bleeding. Adopting a variable target threshold may enhance objective one and two, maximizing benefits with appropriate allocation of resources.

In addition to WAPPS-Hemo, the study will involve two other tools available to hemophilia treaters in Canada: the Canadian Bleeding Disorders Registry (CBDR) and Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire. In particular, this study will leverage the integration of the three tools described above: WAPPS-Hemo, with its ability to generate PK estimates and use them to optimize treatment regiments; CBDR, already collecting most of the information needed to both generate and estimate optimal regimen recommendations for tailoring an individual regimen to meet specified treatment goals; and PROBE, to measure the impact on patient critical life experiences and outcome.

Eligibility criteria: Inclusion Criteria:

* individuals with severe congenital hemophilia A and B;
* on continuous factor prophylaxis;
* must be registered on CBDR (iCHIP in BC)

Exclusion Criteria:

* a history of explicit and documented previous treatment tailoring based on pharmacokinetic profiling;
* another congenital or acquired bleeding disorders other than Hemophilia A or B;
* active inhibitors (\> 5 Bethesda units) or currently undergoing immune tolerance induction.

Primary outcomes:
measure: Change in patient quality of life
timeFrame: Completed every 3-6 months for duration of the study, from enrollment to study completion.
measure: Annualized Bleeding Rate (ABR) pre and post-tailoring implementation
timeFrame: Recorded throughout the 2 year duration of the study as they occur.
Secondary outcomes:
measure: Change in physical activity
timeFrame: Completed every 3-6 months for duration of the study, from enrollment to study completion.
measure: Adherence to prescribed regimen
timeFrame: Recorded throughout the 2 year duration of the study - frequency is as input by patient.
measure: Consumption of factor concentrates
timeFrame: Recorded throughout the 2 year duration of the study - frequency as input by patient.
measure: Feasibility and acceptability of the WAPPS-Hemo based prophylaxis tailoring
timeFrame: Recorded after 1 year at the time of tailoring implementation.
measure: Characteristics of reported bleeds
timeFrame: Recorded throughout the 2 year duration of the study- frequency as input by patient.
measure: Assessment of the predictive performance of the WAPPS-Hemo clinical calculator
timeFrame: Measured within routine clinical practice for 12 months post-tailoring implementation.
measure: Change in joint function
timeFrame: Measured at study enrollment and at 2 years at study completion.
Other outcomes:
Locations:
city: Calgary
country: Canada
facility: University of Calgary
state: Alberta
city: Edmonton
country: Canada
facility: University of Alberta
state: Alberta
city: Vancouver
country: Canada
facility: University of British Columbia
state: British Columbia
city: Winnipeg
country: Canada
facility: University of Manitoba
state: Manitoba
city: Hamilton
country: Canada
facility: McMaster University
state: Ontario
city: Hamilton
country: Canada
facility: McMaster University
state: Ontario
city: Kingston
country: Canada
facility: Queen's University
state: Ontario
Study officials:
affiliation: McMaster University
name: Alfonso Iorio, MD, PhD, FRCPC
role: PRINCIPAL_INVESTIGATOR
References: